- EvokAI Creative Labs (TSXV:OKAI) has acquired Finnish MedTech company Head Instruments Oy
- Head Instruments Oy creates smart medical devices and solutions to improve patients’ quality of life and support medical professionals in their work
- Head Instruments Oy has gained widespread recognition for its innovations in the field of Parkinson’s disease
- EvokAI Creative Labs Inc. (OKAI) opened trading at C$2.14 per share
EvokAI Creative Labs (TSXV:OKAI) has acquired Finnish MedTech company Head Instruments Oy.
The medtech artificial-intelligence-powered company acquired 100 per cent of the issued and outstanding securities of Head Instruments Oy by issuing 3,724,674 of its common shares.
Head Instruments Oy creates smart medical devices and solutions to improve patients’ quality of life and support medical professionals in their work.
EvokAI Creative Labs’ CEO and Director, Alejandro Antalich, explained that with this acquisition, his team gains access to its cutting-edge technologies, including advanced neural interfaces, data-driven disease modeling, and personalized treatment solutions.
“These innovations have the potential to significantly transform the diagnosis, monitoring, and therapeutic interventions for Parkinson’s disease patients, addressing critical unmet needs in the field.”
He added that Head Instruments Oy has gained widespread recognition for its innovations in the field of Parkinson’s disease and has developed technology aimed at improving the lives of patients affected by that neurological disorder.
EvokAI Creative Labs Inc. deploys machine learning models to search medical data and uncover insights to help improve health outcomes, patient experiences, drug development, preclinical and clinical decisions, and provide more accurate diagnoses. EvokAI tailors its AI algorithms across the whole healthcare system, from hospitals, private clinics, research institutions, pharmaceutical companies, contract research organizations to medical professionals, patients, healthy individuals aiming at preventing and early detecting any kind of disease and beyond, protecting the aging genome. Earlier this month, the company acquired AI-powered company Rehaboo Oy, click here to read more.
EvokAI Creative Labs Inc. (OKAI) opened trading at C$2.14 per share.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.